Paris, France and Camberley, UK – 18 June 2021 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it will report its audited
Breakthrough data on the successful encapsulation of a biologic using Q-Sphera technology Significant progress across multiple other R&D programmes
DeepMatter (AIM: DMTR), the AIM-quoted company focusing on digitising chemistry, has been selected as a partner for the University of Leeds following a £1.4M EPSRC investment they received to develop
Further to Open Orphan’s announcement on 14 June 2021 in relation to the distribution in specie, the boards of Open Orphan and Poolbeg Pharma are pleased to announce Poolbeg’s intention
Tiziana Responds to UK Call for Development of Innovative ‘Take Home’ Treatments for COVID-19 Disease
Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, notes the recent media comment that Mologic Ltd have requested for Porton Down to evaluate
Evgen Pharma plc (AIM: EVG), a clinical stage drug development company, announces further progress and an update on clinical trial plans for SFX-01 in glioblastoma (“GBM”).
Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials ,
Registration of Avacta’s AffiDX® SARS-CoV-2 Antigen Lateral Flow Test in EU
Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials.
DeepMatter (AIM: DMTR), the AIM-quoted company focusing on digitising chemistry, confirms that the Annual Report and Accounts for the year ended 31 December 2020 and the Notice of Annual General
